CHI ADVISORS LLC
Q1 2023 Form 13-F
NEW YORK, NEW YORK
CIK 0001791468
· CRD 304684
· SEC-registered investment adviser
$376.7M Reported Value Total
CHI ADVISORS LLC reports 6 total accounts under management (AUM). There are 6 discretionary accounts valued at $1,156,715,814, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
SEC Registered
Discretionary Manager
Private funds (Form ADV)
7 funds
· $1.2B gross asset value
Private Equity Fund: $1.2B
Source: Form ADV filed 2023-06-05
Reported value
$376.7M
Quarter over quarter
+1.0%
Holdings
23
Top-10 concentration
89.7%
Key People
Form ADV owners & control persons
Michael G Benwitt
GENERAL COUNSEL, CHIEF OPERATING OFFICER, COWEN INVESTMENT MANAGEMENT LLC
Ashley Paige Latourelle
CHIEF COMPLIANCE OFFICER
Elizabeth Rachel Rosman
HEAD OF INVESTMENT MANAGEMENT, COWEN INVESTMENT MANAGEMENT LLC
Filing Navigation
13F Metrics
Loading 13F Metrics
Q1 2023 13F record
Q1 2023 13F filing summary
| Period of report | March 31, 2023 |
|---|---|
| Filed | May 11, 2023 |
| Form | 13F-HR |
| Reported value | $376.7M |
| Positions | 23 |
| Change in reported value | +0.3% |
| New positions | 4 |
| Exited positions | 3 |
| Position turnover | 26.9% |
| Top-10 concentration | 89.7% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2023 13F
Filed Nov 13, 2023
|
26 | $252.3M |
|
Q2 2023 13F
Filed Aug 11, 2023
|
25 | $329.6M |
|
Q1 2023 13F
Filed May 11, 2023
|
23 | $376.7M |
|
Q4 2022 13F
Filed Feb 13, 2023
|
22 | $375.5M |
|
Q3 2022 13F
Filed Nov 9, 2022
|
25 | $371.9M |
|
Q2 2022 13F
Filed Aug 12, 2022
|
25 | $261.8M |
|
Q1 2022 13F
Filed May 16, 2022
|
21 | $235.2M |
|
Q4 2021 13F
Filed Feb 11, 2022
|
20 | $301.3M |
|
Q3 2021 13F
Filed Nov 15, 2021
|
19 | $342.6M |
|
Q2 2021 13F
Filed Aug 11, 2021
|
18 | $429.9M |
|
Q1 2021 13F
Filed May 14, 2021
|
21 | $499.5M |
|
Q4 2020 13F
Filed Feb 12, 2021
|
20 | $355.0M |
|
Q3 2020 13F
Filed Nov 12, 2020
|
21 | $281.1M |
|
Q2 2020 13F
Filed Aug 12, 2020
|
19 | $256.3M |
|
Q1 2020 13F
Filed May 14, 2020
|
13 | $42.4M |
|
Q4 2019 13F
Filed Feb 14, 2020
|
12 | $132.6M |
|
Q3 2019 13F
Filed Nov 12, 2019
|
13 | $102.7M |
Top 20 holdings · Q1 2023
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | RXDX PROMETHEUS BIOSCIENCES INC | $100.3M | 26.61% |
| 2 | PLRX PLIANT THERAPEUTICS INC | $79.8M | 21.2% |
| 3 | VECT VECTIVBIO HLDG AG | $44.7M | 11.87% |
| 4 | CGEM CULLINAN ONCOLOGY INC | $34.3M | 9.1% |
| 5 | RPTX REPARE THERAPEUTICS INC | $29.5M | 7.83% |
| 6 | LRMR LARIMAR THERAPEUTICS INC | $12.4M | 3.3% |
| 7 | KROS KEROS THERAPEUTICS INC | $11.1M | 2.96% |
| 8 | CMPX COMPASS THERAPEUTICS INC | $9.3M | 2.46% |
| 9 | TSVT 2SEVENTY BIO INC | $8.7M | 2.32% |
| 10 | INZY INOZYME PHARMA INC | $7.7M | 2.04% |
| 11 | OMGA OMEGA THERAPEUTICS INC | $6.4M | 1.69% |
| 12 | IKNA IKENA ONCOLOGY INC | $5.7M | 1.52% |
| 13 | RLYB RALLYBIO CORP | $4.3M | 1.15% |
| 14 | ORTX ORCHARD THERAPEUTICS PLC | $4.2M | 1.12% |
| 15 | KDNY CHINOOK THERAPEUTICS INC | $3.1M | 0.83% |
| 16 | DTIL PRECISION BIOSCIENCES INC | $2.6M | 0.69% |
| 17 | OVID OVID THERAPEUTICS INC | $2.2M | 0.59% |
| 18 | KZR KEZAR LIFE SCIENCES INC | $2.2M | 0.57% |
| 19 | FRLN FREELINE THERAPEUTICS HLDGS | $2.2M | 0.57% |
| 20 | CRVS CORVUS PHARMACEUTICALS INC | $2.1M | 0.57% |
Values as reported on the Q1 2023 Form 13F. Every position is in the holdings table below.